Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the disease and yet another regulatory setback in another.
Tolebrutinib was one of three oral BTK inhibitors that Sanofi acquired as part of its $3.7 billion buyout of Principia ...
13don MSN
From dismissed to finding confidence: What it's like living with a chronic, invisible illness
In 2010, at just 20 years old, Chelsea Ashe started losing vision in her left eye and developed severe double vision. Several ...
Everyday Health on MSN
When MS and RA co-occur: How to cope
MS and RA can occur together and share some symptoms. Managing both conditions works best when you coordinate care and treatment with a neurologist and a rheumatologist.
From this month, the cost of a 10-minute, six-monthly Ocrevus (ocrelizumab) subcutaneous injection for relapsing-remitting multiple sclerosis (MS) will be slashed from more than $16,500 to $31.60 for ...
Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton kinase (BTK) inhibitor fenebrutinib, along with data ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presents new data for Ocrevus ® (ocrelizumab) and the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib at the ...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback